Plasma microRNA biomarkers for multi-organ injury prediction in trauma patients

Boyang Ren[1,2], Chien-Yu Lin[1], Ruoxing Li[3], Chanhee Park[1,2], Ziyi Li[3], Sheng Wang[1,2], Andrew O. Suen[1,2], John Kessler[1,2], Shiming Yang[1], Rosemary Kozar[1], Lin Zou[1,2], Brittney Williams[1,2], Peter Hu[1, *], Wei Chao[1,2,4*]

[1]Translational Research Program, Department of Anesthesiology, University of Maryland School of Medicine; Baltimore, MD, USA
[2]Center for Shock, Trauma and Anesthesiology Research, University of Maryland School of Medicine; Baltimore, MD, USA
[3]Department of Biostatistics, The University of Texas MD Anderson Cancer Center; Houston, TX, USA
[4]Lead contact

*Correspondence:
Peter Hu, PhD; ph@som.umaryland.edu
Wei Chao, MD, PhD; wchao@som.umaryland.edu

Abstract

Trauma remains a leading cause of morbidity and mortality in part due to secondary multi-organ injury. However, our ability to predict the downstream pathophysiology and adverse outcomes of trauma is limited. Here, we select a panel of microRNAs (miRNAs) biomarker candidates based on plasma RNA-Seq analysis of trauma patients and the unique pro-inflammatory nucleotide motif structures identified via a machine learning-guided computer exhaustive search algorithm. We test the panel of plasma miRNAs for their association with various trauma pathophysiological markers and their ability to predict organ injury and immune responses to trauma. We find a marked elevation of these plasma miRNAs as well as multiple inflammatory and organ injury factors at time of admission in a cohort of 48 blunt trauma patients. The plasma levels of these miRNA biomarkers are highly associated with multiple pathophysiological markers known for organ injury, coagulopathy, endothelial activation, and innate inflammation. AUROC analyses indicate that these miRNA biomarkers possess strong abilities to distinguish trauma severity, brain and liver injuries, metabolic acidosis, coagulopathy, and innate inflammation. These observations offer insights into potential values of the selected plasma miRNAs in prediction of trauma pathophysiological risk and clinical outcomes.

Keywords: trauma, RNAseq, miRNAs, biomarkers, organ injury, nucleotide motif, coagulopathy, inflammation, machine learning

Introduction

Trauma is accountable for 13% of death and remains the leading cause of mortality among individuals age 1-44 years in the US.[1] While advancements in the clinical management of traumatic injury has improved survival, the morbidity and mortality of severe injury is still high in part due to secondary multi-organ injury resulting from complex pathophysiological responses to initial trauma.[2] Current treatment of trauma remains limited to supportive therapies and targeting individual pathophysiology such as coagulopathy. Moreover, trauma patients are highly heterogeneous in demographics, underlying pathophysiological responses, and responses to treatments, and as a result, their post-injury clinical trajectories are often unpredictable. These challenges highlight the urgent need for the tools that could help predict the critical pathophysiological changes as well as the downstream adverse clinical outcomes, such as cytokine storm, coagulopathy, organ injury, and death, after initial trauma.

Trauma elicits rapid activation of innate immunity and repair mechanisms in an attempt to restrict the damage.[3-5] However, the innate immune activation can become grossly imbalanced and drive excessive inflammatory response, endothelial injury, cellular barrier dysfunction, and coagulopathy when initial injury is severe and sustained.[3,6] In the absence of infection, danger-associated molecular patterns (DAMPs), released from injured cells, are the potential driver in maintaining and exacerbating the sustained activation of the innate immune system via pattern recognition receptors and subsequent organ injury.[3,6] As such, a forward feedback loop of tissue damage is formed leading to inflammation that in turn causes further cellular and organ impairment.

Studies have found that extracellular RNA, derived from the plasma, tissues, and cells under various pathological conditions, is a strong innate immune activator.[7-10] Extracellular microRNAs (ex-miRNAs) are the dominant biotype of plasma small RNA in both rodents and humans and are markedly differentially expressed, representing a unique signature of plasma miRNAs in trauma.[10] Ex-miRNA, short and single-stranded non-coding RNA molecule, has been proposed to act as a key driver in the innate immune response via TLR7 signaling and the downstream organ injury in trauma and sepsis.[10-12] The potential of plasma miRNAs as biomarkers to predict trauma pathophysiology and clinical outcome has not been well investigated.

Here we selected a panel of 12 plasma miRNAs based on their differential expression in trauma versus healthy subjects and the presence of unique pro-inflammatory nucleotide motifs in their structures, which were identified via a machine learning-guided computer exhaustive search algorithm. We report that in a cohort of 48 patients with blunt trauma, this panel of miRNA biomarker candidates is closely associated with injury severity score (ISS) and a wide spectrum of trauma pathophysiological markers known for organ injury, coagulopathy, endotheliopathy, and inflammation. The plasma miRNAs can distinguish between severe and moderate organ injury, innate immune, and overall injury severity. Measurements of these miRNA biomarkers in trauma patients thus enable us to correlate multi-factors of trauma pathophysiology and to predict the adverse outcome of trauma patients.

Results

Study design

Fig. 1 illustrates the overall design of the current study – motif discovery, biomarker selection, and biomarker evaluation. Previous studies show that some, but not all, plasma miRNAs in mice and humans are differentially expressed after traumatic injury and promote cytokine and complement production via TLR7.[10] In this study, we tested the hypothesis that specific nucleotide sequences or motifs exist in these small RNA molecules that determine the proinflammatory property of miRNAs and can be used to guide the selection of miRNA biomarker candidates for trauma-induced inflammation and organ injuries. To achieve this, we developed a computer exhaustive search algorithm and identified five nucleotide motifs embedded specifically in pro-inflammatory miRNAs (**Fig. 1,** *left panel*). Next, to select miRNA biomarker candidates, 10 patients with severe injury and 10 healthy controls were analyzed for RNA-Seq-based plasma RNA profiles. Based on the differential expression (DE) of the plasma miRNAs and the presence of any one of the five nucleotide motifs in their structures, we selected a panel of plasma miRNA biomarker candidates that were upregulated in trauma patients and possessed a proinflammatory property (**Fig. 1,** *middle panel*). Finally, we tested the panel of miRNA biomarker candidates in a cohort of 48 trauma patients and 24 healthy subjects for their association with various trauma pathophysiology markers known to be linked with organ injury, coagulation, inflammation, and endothelial activation. We also tested the predictive ability of the miRNA biomarkers in organ injury after initial trauma (**Fig. 1,** *right panel*).

Human study subjects

Table 1 lists the demographic and clinical information of the trauma and healthy cohorts. The median age of the trauma and control groups was 29.0 and 30.5 years old, respectively, although the trauma group had a wider range of age distribution (**Fig. S1A**). Males represents 65% of the trauma cohort and 42% of the healthy group (**Fig. S1B**). The average ISS score was 15 (4-43) among the trauma cohort. Eighteen patients had severe injury with ISS > 15, an indicator of severe injury, and consequently had a longer hospital stay than those with less severe injury (**Fig. S1C-D**). **Table 1** and **Fig. S1E** illustrates the injury patterns present on arrival. Notably, while most of the patients had bone fracture(s), 18 patients also sustained at least one internal organ injury including lung, spleen, aorta, bowel, mesentery, kidney, and liver.

Machine learning-guided discovery of pro-inflammatory motifs in miRNAs

To identify the nucleotide motifs embedded specifically in pro-inflammatory, but not in non-inflammatory, miRNAs, we developed a computer exhaustive search algorithm and took a machine learning approach for automated motif selection. As illustrated in **Fig. 2A**, we first generated a training data set containing 33 mouse miRNAs that are upregulated in the plasma of trauma mice.[10] Among the 33 miRNA mimics tested in an in vitro cell system (cultured bone marrow-derived macrophages, BMDMs), 18 of them triggered a dose-dependent CXCL2 (Chemokine (C-X-C motif) ligand 2) production while the other 15 did not (non-inflammatory) as shown in **Fig. 2B**. Utilizing the search algorithm (**Table S1**), a list of 513,599 possible motifs ranging between 2mer – 10mer within the training set of 33 miRNAs were identified. The list of motifs was then shortened to 306 after we

excluded those motifs that appeared in the non-inflammatory miRNAs, those that appeared in less than 25% of pro-inflammatory miRNAs, and those with duplicates. Thus, the remaining motifs were only present in the pro-inflammatory miRNAs (**Fig. 2A**). Next, we developed an automated motif-finding algorithm to pinpoint the most essential motifs linked to the pro-inflammatory property of miRNAs by utilizing the Least Absolute Shrinkage and Selection Operator (LASSO) regression model.[13] By applying cross-validation and tuning the value of the regulator in the LASSO model, only essential motifs would be left with non-zero coefficients while retaining highest model performance monitored by F1 score (**Fig. S2**). As a result, five motifs – 1) .UUC, 2) U..UU., 3) .A.....UU., 4) G.UU. and 5) UU...U ("." represents a wild card) – were identified specifically link to the 18 pro-inflammatory miRNAs of the training set (**Fig. 2A**), and a total of 41 pro-inflammatory motifs were discovered in the training set of miRNAs with a relaxed LASSO algorithm (**Table S2**). These data indicate that the five motifs are the most prevalent in the 18 pro-inflammatory miRNAs but completely absent in the 15 non-inflammatory miRNAs. **Fig. 2B** details the 33 miRNAs – 18 pro-inflammatory and 15 non-inflammatory – and their tested vs. motif-based predicted results of CXCL2 production in BMDMs. As illustrated in **Fig. 2B** and **Table 2**, the sensitivity of the individual motifs to identify pro-inflammatory miRNAs in the training set was between 56% ~ 61% with the specificity at 100%. However, the five motifs together – *i.e.,* presence of any of the five – could distinguish pro-inflammatory miRNAs from non-inflammatory miRNAs with 100% sensitivity and 100% specificity.

We next validated our algorithm in two separate sets of miRNAs - Test set 1 consisted of 20 mouse miRNAs upregulated in either a mouse model of sepsis or polytrauma in a previously published plasma small RNA-seq database (**Fig. 2C**).[10, 12] Test set 2 consisted of 38 human miRNAs that were found upregulated in the plasma of our trauma cohort based on previous plasma small RNA-Seq (**Fig. 2D**).[10] Both sets of miRNAs were completely different from those in the training set. In these test sets, a dose-dependent cytokine CXCL2 production by cultured BMDMs treated with the miRNA mimics was considered the "ground truth" to define the "pro-" *vs* "non" inflammatory" miRNAs (**Fig. S3**). As illustrated in **Fig. 2C-D** and detailed in **Table 2**, the 5 motifs together (*i.e.,* any one of the five motifs) offered an overall prediction with 92% sensitivity and 86% specificity in Test set 1 and 84% sensitivity and 69% specificity in Test set 2. These data suggest that five miRNA nucleotide motifs possess strong sensitivity and reasonable specificity to predict the pro-inflammatory property of miRNAs and were used to guide the selection of miRNA biomarker candidates in trauma patients.

Motif-guided selection of miRNA biomarker candidates in trauma
To select plasma miRNA biomarker candidates in trauma patients, we first identified the upregulated plasma miRNAs in response to trauma based on our published RNA-Seq data (n=10, trauma vs n=10, health) at the time of admission.[10, 11] Among 401 miRNAs detected in the human plasma, 151 were upregulated with a fold-change (FC) > 1.5 in the trauma patients. These upregulated miRNAs were further filtered by top 50% of FC and top 50% of the highest abundance as measured by their count per million (CPM) in RNA-Seq analysis. Finally, we applied the motif-finding algorithm to the remaining 38 miRNAs and identified 18 miRNAs containing at least one of the motifs. The top 12 miRNAs with

the lowest false discovery rate (FDR) values were selected as the biomarker candidates (**Table 3**). Among the 12 miRNA candidates, all contain one or more of the five motifs and have been confirmed as "pro-inflammatory" by the in vitro cytokine testing in BMDMs.

Plasma miRNA biomarker candidates are markedly elevated in patients with blunt trauma

Next, we measured the plasma miRNA biomarker candidates in the entire trauma (n=48) and healthy (n=24) cohorts. Using state of the art digital PCR (dPCR) technology, we were able to quantify the copy number of the miRNA biomarkers in the plasma and found that all 12 miRNAs were highly expressed and markedly upregulated in trauma patients as compared to the healthy control (**Fig. 3A**). The fold-changes of trauma vs. control subjects ranged from 6.7 (let-7c-5p) to 78.2 (hsa-miR-145-5p). Moreover, in severely injured patients (ISS>15), 9 out of the 12 miRNA biomarker candidates exhibited significantly higher plasma levels than those in moderately injured patients (ISS≤15) (**Fig. 3B**). The heatmap in **Fig. 3C** illustrates the 48-patient trauma cohort and 24 healthy participants and their relative plasma expression of the 12 miRNA candidates. The heatmap reveals that the trauma patients were highly heterogenous in their plasma levels of the 12 miRNA candidates, but some trauma patients, particularly many severely injured with ISS>15, showed a cross-board marked upregulation of the 12 miRNA biomarkers.

Plasma miRNAs biomarker candidates are closely correlated with trauma pathophysiology

The pathophysiology of trauma-induced secondary injury is complex. Immediate effects of trauma include the direct and indirect mechanical force on tissues, which induces tissue damage, contusions, hemorrhage, fractures, and disrupted barrier immune defenses.[3, 5] Subsequent innate immune responses driven by DAMPs lead to excessive inflammation, endothelial injury, and coagulopathy. These pathophysiological events, often interlinked, result in hemodynamic instability, microvascular thrombosis, vascular leak, tissue hypoxia, secondary organ injury, and other clinical complications. To capture these critical events, we have designed and tested an extensive panel of mediators and injury markers that are linked to the trauma pathophysiology. We utilized a Luminex-based multiplex assay system to measure 14 key protein mediators and markers present in the plasma at the time of admission, which included 1) various organ injury markers, 2) pro-coagulants, 3) pro-inflammatory cytokines and chemokines, and 4) mediators of endothelial activation. As illustrated in **Fig. 4A**, there was a marked and trauma severity-dependent increase in the brain injury markers S100B[14, 15] and enolase[15] among the trauma cohort. A similar increase was observed with the lung injury markers of ANG2/ANG1.[16] D-dimer, a fibrin degradation product, was markedly elevated, so were the two plasma pro-coagulants P-selectin and tissue factor in these trauma patients. Traumatic injury also led to vascular inflammation as evidenced by a significant increase in the pro-inflammatory mediators IL-6, TNFα, IL-8, and CXCL2 in the plasma. Also observed was marked endothelial cell activation and injury. Syndecan-1, a proteoglycan expressed on endothelial cells and a marker for endothelial injury, was notably increased in severely-injured patients with ISS >15. Both vWF-A2 and VCAM-1 exhibited an injury severity-dependent and marked increase after trauma. We next performed Pearson's correlation analyses between the panel of 12 miRNA biomarkers and the various plasma protein injury and inflammation

markers linked to trauma pathophysiology. As illustrated in **Fig. 4B**, we discovered that majority of the 12 ex-miRNA biomarker panel was either moderately ($r > 0.4$, $p < 0.01$) or strongly ($r > 0.7$, $p < 0.01$) quantitatively correlated with various plasma inflammatory and injury markers, such as brain injury (S100B and enolase 2), coagulation (D-dimers), inflammation (IL-6 and IL8), and endothelial injury (syndecan-1, vWF-A2).

Plasma miRNA biomarkers are correlated with organ injury and coagulation in trauma

Standard clinical blood tests at the time of admission provide critical information about trauma pathophysiology such as organ injury, coagulopathy, and tissue metabolism. As shown in **Fig. 5A**, most trauma patients exhibited elevated levels of AST and ALT, two liver injury markers, but not much with total bilirubin and alkaline phosphatase. Blood lactate, an indicator of tissue ischemia and anaerobic metabolism, was elevated in most trauma patients and even higher in severely injured patients. Less severely injured patients had normal coagulation function as evidenced by largely normal PTT, PT, and INR, and normal kidney function with normal creatinine and BUN in both mild and severely injured patients. While blood cell (WBC) was abnormally high in injured patients, platelets and hemoglobin remained normal in this cohort of trauma patients. Importantly, Pearson correlation analyses revealed that the panel of miRNA biomarkers, with exception of miR-224-5p and miR-125b-2-3p, were closely correlated with the liver enzymes AST and ALT, as well as total bilirubin and PT/INR even though values were largely within the normal ranges (**Fig. 5B**). These same miRNA candidates were also highly correlated with the ISS, a parameter calculated based on injuries in different body regions and not calculated until after hospital discharge. Notably, a few miRNA biomarkers, such as miR-199a-3p, miR-148a-3p, miR-145-5p, miR-145-3p, miR-125a-5p, miR-199a-5p, and miR-125b-2-3p, were negatively correlated with platelet count although within normal range.

Prediction of organ injury in trauma using plasma miRNA biomarkers

We evaluated the abilities of the plasma miRNA biomarkers in distinguishing between severe and moderate trauma-induced systemic inflammation and secondary organ injury. We divided the pathophysiological and clinical organ injury markers into severe and moderate groups at the median levels. For overall injury severity, we grouped patients based on their injury severity score (ISS), with >15 as severe trauma.[17] Random forest regression with two-fold cross-validation was performed to analyze the panel of 12 plasma miRNA biomarkers against various injury markers. As illustrated in **Fig. 6**, the Areas Under Receiver Operating Characteristics Curves (AUROC) [95% confidence intervals, CI] of the 12-miRNA panel for predicting liver injury were 0.80 [0.67-0.93] for ALT, 0.76 [0.62-0.90] for AST, and 0.75 [0.57-0.92] for total bilirubin. Similarly, the AUROC for brain injury markers were 0.85 [0.74-0.94] (Enolase 2) and 0.85 [0.72-0.98] (S100B), for plasma lactate was 0.76 [0.60-0.90], for ISS it was 0.72 [0.55-0.88], for coagulation indicator D-dimer, it was 0.78 [0.64-0.93] and finally for inflammation, it was 0.7 [0.54-0.87] (IL-6) and 0.7 [0.53-0.76] (IL-8). As anticipated, age and sex as a reference were not associated with the severity of various organ injury and had near 0.5 AUROC values, indicating their poor performance in the trauma injury marker prediction. Notably, the miRNA biomarker panel performed relatively weak in their ability to distinguish the levels of coagulation factors (P-selectin, tissue factor, PTT, PT, INR), endothelial cell

activation markers (syndecan-1, vWF-A2 and VCAM-1), and lung injury markers (ANG1 and ANG2) (**Fig. S4**). Finally, we evaluated whether ISS could distinguish the severity of organ injuries as predicted by the 12-miRNA panel. The results indicated that ISS had partial success in distinguishing brain injury severity (Enolase2, AUROC 0.70), plasma lactate (0.71), the coagulation indicator D-dimer (0.77) and inflammation (IL6, 0.77) (**Fig. S5**).

Discussion

Our findings provide proof-of-concept that plasma miRNAs could be used as biomarkers in traumatic injury that are not only closely associated with various signature markers linked to trauma pathogenesis such as inflammation, coagulopathy, and endotheliopathy, but also possess moderate and strong predictive abilities for these early pathological outcomes. Notably, these pathophysiological markers, while not standard clinical laboratory tests, offer a molecular lens into the wide spectrum of pathophysiological responses in the event of traumatic injury. These finding support the hypothesis that extracellular plasma miRNAs and the subsequent innate immune signaling are the upstream drivers that may be responsible for some of the key pathophysiological responses to traumatic injury such as inflammation and secondary organ injury.[10, 11]

A number of studies have investigated the diagnostic and prognostic values of blood biomarkers, both proteins and nucleic acids, in traumatic brain injury (TBI).[18-22] Several studies have shown that plasma miRNAs are differentially expressed upon TBI and some have been proposed as TBI biomarkers.[22-25] In our study, we selected the panel of 12 plasma miRNAs as biomarker candidates based on their large differential expression in trauma patients as compared with healthy controls, their high abundance in the plasma samples, and the presence of pro-inflammatory motifs in their nucleotide sequences. The computer searching algorithm-based machine learning strategy enables us to identify and validate the five motifs that offer strong prediction for the pro-inflammatory property of the tested miRNAs with excellent sensitivity and moderate specificity. It is noteworthy that the five essential motifs all include a UU dimer, which is consistent with a previous crystallographic study that successive uridine-containing single-stranded RNA fully or moderately bind TLR7, whereas single uridine-containing ssRNAs have reduced affinities.[26] The importance of the UU dimer in one of the motifs, UU…U, has been evidenced by abolishment of miR-146a-5p-stimuated and TLR7-dependent inflammatory cytokine production when its UU…U motif was mutated to AU…U or UA…U.[12] Thus, the identification of these specific motifs represents a unique strategy that links the inflammatory property of plasma miRNAs and miRNA biomarker selections in trauma and other clinical conditions where innate immune activation and inflammation are a critical part of disease pathogenesis, such as sepsis,[27] shock,[3, 27] reperfusion injury,[28, 29] neurodegeneration,[30] pain,[31] and cancer metastasis.[32]

Our data revealed the diverse physiological and pathophysiological responses in the cohort of trauma patients such as liver injury, brain injury, coagulation activation, systemic inflammatory syndrome, and endothelial activation. It is noteworthy that there was no clinically recognizable coagulopathy or acute kidney injury in these patients given the normal INR and BUN/Creatinine at the time of admission. The majority of patients (63%)

had relatively mild injury with ISS ≤ 15. The samples were collected very early at the time of arrival before severe clinical coagulopathy and acute kidney injury could potentially develop. Nevertheless, the finding that the plasma miRNA biomarkers exhibit a moderate-to-strong correlation with the individual protein mediator of injuries suggest a potential molecular link between the plasma miRNAs and the pathophysiological events. Previous data have supported the role of extracellular miRNA and its downstream TLR7 signaling in inflammatory response,[12] endothelial dysfunction,[33] organ injury,[10, 12] and coagulopathy[34] during sepsis and trauma.[11] Together, these data support the hypothesis that these miRNA biomarkers are not only associated with the downstream pathophysiological changes in response to traumatic injury, but also likely play a contributory role.

Our data provide a proof-of-principle that the miRNA biomarker panel confers fairly strong abilities in predicting the severity of organ injury such as the liver and brain injury, overall trauma severity scores, metabolic acidosis, coagulation activation, and circulating cytokine storm. If validated in future prospective studies of larger independent cohorts, the plasma miRNA biomarkers could help to identify individuals who are at risk for secondary multi-organ injury and other clinical outcomes such as mortality following severe injury and as such, to guide individualized clinical management of trauma patients.

Limitations of the study
Several limitations exist in the current study. One limitation is the lack of external trauma cohort to validate the performance of the miRNA biomarkers. An independent and larger trauma cohort will be needed to further test the utility of the miRNA biomarkers and generalize their clinical application. The relatively small cohort size in the current study, while it was adequate for differential expression and correlation discovery, could impact the ROC analyses and performance assessment of the predictability of the miRNA biomarkers. Finally, the cohort of blunt trauma patients in this study had relatively modest severity without associated mortality. While various immune mediators and injury markers significantly increased following the initial trauma, most clinical injury markers remained within the normal ranges at time of trauma center arrival when blood samples were drawn. Analyzing longitudinal plasma samples in more severely injured patients in future prospective study will help quantify ongoing development of trauma-induced secondary organ injury and other adverse clinical outcomes, and further evaluate the prognostic value of these novel miRNA biomarkers.

Methods

Human study subjects

This prospective observational cohort study was conducted at the Shock Trauma Center of the University of Maryland. The protocol for this study was conducted in accordance with the policies and procedures approved by the Institutional Review Board of the University of Maryland (IRB protocol: HP-0011660). The inclusion criteria include: 1) patients at age between 18-45, 2) patients with serious injury defined as one of the following: blunt injury to chest, abdomen, or pelvis, two or more long-bone fractures (tibia, femur, or humerus), and traumatic amputation proximal to wrist or ankle. Exclusion criteria include: 1) vulnerable population (pregnancy, prisoners, inmates), 2) two or more systemic diseases such as hypertension, diabetes, and smoking, 3) penetrating injury to the chest or abdomen, 4) unknown time of injury, 5) suspected toxic ingestion, 6) non-survivable brain injury, CT evidence of intracranial hemorrhage, 7) burns > 50% BSA$^{\%}$, and 8) immunosuppressed. For the healthy cohort, age and sex-matched between age 18-45 were recruited with the exclusion criteria of 1) vulnerable population and 2) subject with two or more systemic diseases. Informed consent was obtained for each subject or their legally authorized representative. Patients were treated according to standard of care per institutional and national guidelines.

Animal use

C57BL/6J mice were purchased from Jackson Laboratory. The animal experimental protocols were approved by the Institutional Animal Care and Use Committee, University of Maryland School of Medicine (IACUC protocol: 0722002).

Computer searching algorithm for miRNA pro-inflammatory motif identification

The algorithm consists of three main components: building a motif list from training set, selecting pro-inflammatory motifs and executing an automated motif-finding algorithm to narrow down to the most essential ones. 1) Motifs ranging from two to ten nucleotides long within miRNA sequences in the training dataset were generated, including those with wildcards. 2) Three exclusion criteria were applied to the motifs. Firstly, exclude motifs that appear in non-inflammatory miRNA sequences. Secondly, motifs that showed up in less than 25% of either group of miRNAs were excluded, to retain those with high abundance. Third, duplicate motifs defined by the same core sequence with differently existed wildcards on either end of the core sequence will be assess for their fitness in the training set, if the performance of duplicates were the same, sequence with the shortest length will be kept. 3) And finally, an automated motif-finding algorithm to pinpoint the most relevant motifs linked to inflammatory responses were developed based on a penalized LASSO (least absolute shrinkage and selection operator) regression model. A 5-fold cross-validation was used to tune the hyperparameter, Lambda, that controls the strength of the L1 regularization term in the LASSO model was adjusted so that the model retained the highest F1 performance score while utilizing the minimal number of non-zero coefficient motifs. Detailed workflow for motif algorithm can be found in Supplementary Table 1.

Patient clinical data

For trauma patients, blood samples were obtained at time of arrival. De-identified patients' demographic and clinical information was obtained for further analysis. The clinical information included patients' demographics, injury mechanism and pattern. The clinical metrics included injury severity score (ISS), aspartate aminotransferase (AST), alanine transaminase (ALT), alkaline phosphatase (Alk phos), total bilirubin, blood urea nitrogen (BUN), creatinine (Cr), lactate, prothrombin time (PT), partial thromboplastin time (PTT), international normalized ratio (INR), and platelet count (PLT), white blood cell (WBC), hemoglobin (Hb), hematocrit (Hct), and potassium (K).

Plasma processing

Whole blood samples were collected in K_2-EDTA tube and centrifuged at 1000 g for 10 minutes at room temperature. Supernatants were centrifuged at 1000 x g for 10 minutes at 4°C, transferred, and centrifuged again at 14,000 x g for 10 minutes at 4°C. Plasma was stored at -80°C until further use.

Plasma miRNA extraction and quantification by digital PCR

Plasma RNA was extracted using Qiagen miRNeasy Serum/Plasma Advanced Kit. Specifically, after adding lysis buffer, 250 μL of human EDTA-plasma was mixed with the spiked-in cel-miR-39-3p and proceeded to RNA purification. Purified RNA was eluted in 20 μL nuclease-free water. Six μL of RNA was used for cDNA synthesis using Qiagen miRCURY LNA RT Kit. The LNA-enhanced primers were designed for Qiagen miRCURY LNA miRNA PCR Assays, and miRNA copy numbers were quantified by a digital PCR platform from Qiagen (QIAcuity One). To calculate the recovery rate and correct for the loss of miRNA during plasma RNA extraction, an equal quantity of the spike-in cel-miR-39-3p was used for cDNA synthesis, quantified using digital PCR without going through the RNA extraction step, and termed as the "added spike-in". The plasma concentration of target miRNA (copies/mL) was calculated as: detected miRNA copies × normalizing factor (*added* spike-in / *detected* spike-in copies) / plasma volume used.

MiRNA mimics

Single-stranded miRNA mimics were synthesized as the same ribonucleotide sequence as human mature miRNAs with modification of phosphorothioate linkages in between the ribose to enhance nuclease resistance and cell transportation. MiRNA mimics were synthesized from Integrated DNA Technologies (IDT) and reconstituted in RNase-free H_2O.

Bone marrow-derived macrophages

Bone marrow-derived macrophages (BMDMs) were prepared from eight to 12-week-old male mice as described previously.[12] Bone marrow cells from the tibias and femurs were suspended in RPMI 1640 medium supplemented with 10% fetal bovine serum, 5% horse serum,10 ng/ml M-CSF, and penicillin/streptomycin at a density of $2×10^6$/mL and cultured in 96-well plate at 100μL/well. Two days after incubation at 37 °C and 5% CO_2, culture medium was changed once before miRNA treatment.

Raw 264.7 macrophage cell line

Murine macrophage cell line Raw 264.7 were cultured in high glucose Dulbecco's Modified Eagle Medium (DMEM) supplied with L-glutamine,10% and penicillin/streptomycin at a density of 3×10^5/mL and cultured in 96-well plate at 100μL/well.

miRNA treatment of cells
Cells were incubated for 2 hours with serum-free medium supplemented with 0.05% BSA. Synthetic miRNA mimics were packaged with Lipofectamine 3000 before added to cell cultures. For Test set 1 and Test set 2, miRNAs were titrated at the concentrations between 3 - 500 nM in cultured media. Eighteen hours later, media were assayed for CXCL2 production using ELISA. miRNAs that induced 1) a dose-dependent increase of CXCL2 in culture medium and 2) at lease 1.5-fold increase CXCL2 production were defined as pro-inflammatory miRNAs.

Luminex multiplex for plasma marker quantification
The concentrations of plasma protein analytes were determined by Luminex Assay (R&D systems), a fluorescent bead-based multiplex immunoassay platform. The analyte panel specifically designed for this study included S100B (S100 calcium-binding protein B), enolase2, ANG1 (angiopoietin1), ANG2 (angiopoietin2), P-selectin, tissue factor, d-dimer, IL-6 (interleukin-6), TNFα (tumor necrosis factor alpha), IL-8 (interleukin-8), CXCL2 (Chemokine (C-X-C motif) ligand 2), syndecan1, vWF-A2 (von Willebrand factor A2 domain) and VCAM1 (vascular cell adhesion protein 1). Plasma samples were thawed on ice and centrifuged at 12,000 x g for 10 min. The supernatants were applied to the antibody-conjugated magnetic bead and proceeded further following the manufacturer's instructions. The fluorescent antibody reaction was measured on a Luminex 200 machine from Luminex xMAP Technology and the analysis was performed with the Luminex xPONENT software.

Predictive modeling and performance evaluation
The injury markers from the Luminex assays or clinical data were binarized based on the corresponding median values. Random forest modeling of all 12 miRNA biomarker candidates to each marker was built. Data were subjected to 2-fold cross-validation (CV) for 100 times before feeding to the model. The mean values of sensitivity and specificity were used for plot ROC curve and the reported 95% confidence intervals (95% CI) were calculated based on all AUROC results from the CV. Receiver operating characteristics (ROC) curve was used to evaluate the performance of the model, and area under ROC (AUROC) was calculated by the trapezoidal rule in R package pROC (v1.18.5).

Data cleaning
Luminex data under detection levels were set to 0. Missing clinical data were noted N/A and skipped in plotting and analysis.

Human plasma RNA-Seq data
RNA-seq dataset were used for selection of test set miRNAs and are available through the Gene Expression Omnibus. **Test set 1:** GSE133733, Small RNA-Seq of mouse plasma from model of polymicrobial sepsis. **Test set 2:** GSE223151, Small RNA-Seq of

human plasma samples and mouse polytrauma. MiRNA biomarkers candidates were selected based on GSE223151.

Software and packages
R Statistical Software (v4.4.0), package pROC (v1.18.5), ROCR (v1.0-11), randomForest (v4.7-1.1), dplyr (v1.0.10), ggplot2 (v3.5.1), ComplexHeatmap (v2.20.0) and ComplexUpset (v1.3.3), Prism GraphPad 10 were used for statistical analysis and data plotting. Python (v3.10) was used for motif discovery.

Power calculation
Based on our plasma RNA-Seq data from a small cohort of severely injured patients (N=10) and age and sex matched healthy controls (N=10),[10] the statistical power reached 0.86 when miRNA biomarkers were measured in the cohorts of 48 trauma patients and 24 controls assuming standard deviation of 12% and a minimum difference in means of 30% between groups.

Statistical analysis
Analysis of the data was performed using R Statistical Software (v4.4.0). Data were tested for normality with QQ plot and Shapiro-wilk test. For variable with a normal distribution (Shapiro-Wilk test, p > 0.05) in all comparison groups, a t-test with Benjamini-Hochberg correction was used. For variable that did not follow a normal distribution, a Wilcoxon test with Holm-Bonferroni correction was used. Statistical details of experiments can be found in the figure legends. Significance is achieved if *p*<0.05.

RESOURCE AVAILABILITY

Lead contact
Further information and requests for resources and reagents should be directed to and will be fulfilled by the lead contact, Dr. Wei Chao (wchao@som.umaryland.edu), Professor and Co-Director, Center for Shock, Trauma and Anesthesiology Research, University of Maryland School of Medicine, Baltimore, MD 21201, USA.

Materials availability
Plasma acquired in this study is available from the lead contact upon request.

Data and code availability
- Data - All data reported in the study will be shared by the lead contact upon request
- The code for statistical analysis and plotting in R program will be shared by the lead contact upon request.
- Any additional information required to reanalyze the data reported in this paper is available from the lead contact upon request.

References

1. Web-based Injury Statistics Query and Reporting System: Top Ten Leading Causes of Death in the U.S. for Ages 1-44. In: *2022*). Centers for Disease Control and Prevention (2022)
2. Rhee P*, et al.* Increasing trauma deaths in the United States. *Ann Surg* **260**, 13-21 (2014)
3. Huber-Lang M, Lambris JD, Ward PA. Innate immune responses to trauma. *Nat Immunol* **19**, 327-341 (2018)
4. Xiao W*, et al.* A genomic storm in critically injured humans. *J Exp Med* **208**, 2581-2590 (2011)
5. Lord JM*, et al.* The systemic immune response to trauma: an overview of pathophysiology and treatment. *Lancet* **384**, 1455-1465 (2014)
6. Messerer DAC, Halbgebauer R, Nilsson B, Pavenstadt H, Radermacher P, Huber-Lang M. Immunopathophysiology of trauma-related acute kidney injury. *Nat Rev Nephrol* **17**, 91-111 (2021)
7. Feng Y*, et al.* Cardiac RNA induces inflammatory responses in cardiomyocytes and immune cells via Toll-like receptor 7 signaling. *J Biol Chem* **290**, 26688-26698 (2015)
8. Zou L, Feng Y, Xu G, Jian W, Chao W. Splenic RNA and MicroRNA Mimics Promote Complement Factor B Production and Alternative Pathway Activation via Innate Immune Signaling. *J Immunol* **196**, 2788-2798 (2016)
9. Feng Y*, et al.* Extracellular MicroRNAs Induce Potent Innate Immune Responses via TLR7/MyD88-Dependent Mechanisms. *J Immunol* **199**, 2106-2117 (2017)
10. Suen AO*, et al.* Extracellular RNA Sensing Mediates Inflammation and Organ Injury in a Murine Model of Polytrauma. *J Immunol* **210**, 1990-2000 (2023)
11. Williams B, Kozar R, Chao W. EMERGING ROLE OF EXTRACELLULAR RNA IN INNATE IMMUNITY, SEPSIS, AND TRAUMA. *Shock* **59**, 190-199 (2023)
12. Wang S*, et al.* Role of extracellular microRNA-146a-5p in host innate immunity and bacterial sepsis. *iScience* **24**, 103441 (2021)
13. Tibshirani R. Regression Shrinkage and Selection via the Lasso. *Journal of the Royal Statistical Society Series B (Methodological)* **58**, 267-288 (1996)
14. Goyal A*, et al.* S100b as a prognostic biomarker in outcome prediction for patients with severe traumatic brain injury. *J Neurotrauma* **30**, 946-957 (2013)
15. Nguyen DN*, et al.* Elevated serum levels of S-100beta protein and neuron-specific enolase are associated with brain injury in patients with severe sepsis and septic shock. *Crit Care Med* **34**, 1967-1974 (2006)
16. Agrawal A*, et al.* Plasma angiopoietin-2 predicts the onset of acute lung injury in critically ill patients. *Am J Respir Crit Care Med* **187**, 736-742 (2013)
17. Palmer CS, Gabbe BJ, Cameron PA. Defining major trauma using the 2008 Abbreviated Injury Scale. *Injury* **47**, 109-115 (2016)
18. Tabor JB*, et al.* Plasma Biomarkers of Traumatic Brain Injury in Adolescents With Sport-Related Concussion. *JAMA Netw Open* **7**, e2431959 (2024)
19. McDonald SJ, O'Brien TJ, Shultz SR. Biomarkers add value to traumatic brain injury prognosis. *Lancet Neurol* **21**, 761-763 (2022)

20. Ghaith HS*, et al.* A Literature Review of Traumatic Brain Injury Biomarkers. *Mol Neurobiol* **59**, 4141-4158 (2022)

21. Hossain I, Marklund N, Czeiter E, Hutchinson P, Buki A. Blood biomarkers for traumatic brain injury: A narrative review of current evidence. *Brain Spine* **4**, 102735 (2024)

22. Di Pietro V*, et al.* MicroRNAs as Novel Biomarkers for the Diagnosis and Prognosis of Mild and Severe Traumatic Brain Injury. *J Neurotrauma* **34**, 1948-1956 (2017)

23. Redell JB, Moore AN, Ward NH, 3rd, Hergenroeder GW, Dash PK. Human traumatic brain injury alters plasma microRNA levels. *J Neurotrauma* **27**, 2147-2156 (2010)

24. Qin X, Li L, Lv Q, Shu Q, Zhang Y, Wang Y. Expression profile of plasma microRNAs and their roles in diagnosis of mild to severe traumatic brain injury. *PLoS One* **13**, e0204051 (2018)

25. Bhomia M, Balakathiresan NS, Wang KK, Papa L, Maheshwari RK. A Panel of Serum MiRNA Biomarkers for the Diagnosis of Severe to Mild Traumatic Brain Injury in Humans. *Sci Rep* **6**, 28148 (2016)

26. Zhang Z*, et al.* Structural Analysis Reveals that Toll-like Receptor 7 Is a Dual Receptor for Guanosine and Single-Stranded RNA. *Immunity* **45**, 737-748 (2016)

27. Angus DC, van der Poll T. Severe sepsis and septic shock. *N Engl J Med* **369**, 840-851 (2013)

28. Yellon DM, Hausenloy DJ. Myocardial reperfusion injury. *N Engl J Med* **357**, 1121-1135 (2007)

29. Chen C*, et al.* Role of extracellular RNA and TLR3-Trif signaling in myocardial ischemia-reperfusion injury. *J Am Heart Assoc* **3**, e000683 (2014)

30. Lehmann SM*, et al.* An unconventional role for miRNA: let-7 activates Toll-like receptor 7 and causes neurodegeneration. *Nat Neurosci* **15**, 827-835 (2012)

31. Park CK*, et al.* Extracellular microRNAs activate nociceptor neurons to elicit pain via TLR7 and TRPA1. *Neuron* **82**, 47-54 (2014)

32. Fabbri M*, et al.* MicroRNAs bind to Toll-like receptors to induce prometastatic inflammatory response. *Proc Natl Acad Sci U S A* **109**, E2110-2116 (2012)

33. Huang H*, et al.* TLR7 Mediates Acute Respiratory Distress Syndrome in Sepsis by Sensing Extracellular miR-146a. *Am J Respir Cell Mol Biol* **67**, 375-388 (2022)

34. Williams B*, et al.* Toll-like receptors 2 and 7 mediate coagulation activation and coagulopathy in murine sepsis. *J Thromb Haemost* **17**, 1683-1693 (2019)

Acknowledgements

This work was supported in part by the National Institutes of Health grant R35-GM140822 (WC). We thank Rashida Mohamed-Hinds from University of Maryland School of Medicine, for collecting and organizing the trauma clinical data. The graphic study design was created with BioRender.com.

Author contributions

Conceptualization, P.H. and W.C.; Methodology, B.R., C-Y.L., R.L., C.P., S.Y.; Investigation, B.R., C-Y.L., R.L., C.P., Z.L., L.Z., B.W., P.H., and W.C.; Writing — original draft, B.R., C-Y. L., and W.C.; Writing — review & editing, Z.L., R.K., L.Z., B.W., P.H., and W.C.; Funding acquisition, W.C.; Resources, L.Z., B.W. and W.C.; Supervision, Z.L., P.H., and W.C.

Patent pending

The authors declare the following competing interests: 1) B.Y., S.Y., P.H., and W.C. are listed as inventors on a U.S. Provisional Application No. 63/734,468 entitled: "*Extracellular miRNA Motifs for Inflammation, Methods of Discovery and Uses Thereof*"; 2) B.Y. and W.C. are listed as inventors on a U.S. Provisional Application No. 63/54,643 entitled: "*Methods for Determining Trauma-Induced Secondary Organ Injury*".

SUPPLEMENTAL INFORMATION

Figure S1-S5:

Figure S1. Demographic and clinical information of the control and trauma cohorts
Figure S2. Selection of essential motifs in LASSO model
Figure S3. CXCL2 production in cultured macrophages treated with miRNA mimics
Figure S4. ROC analysis for protein mediators and injury markers with AUROC <0.7
Figure S5. ROC analysis with ISS as the predictor

Table S1-S2:

Table S1. Computer exhaustive search algorithm
Table S2. Pro-inflammatory motifs identified with a relaxed LASSO algorithm

Figure 1. Overall study flow.
The study consists of the following three parts: 1) Motif discovery (*left panel*): Five pro-inflammatory motifs are identified via a computer exhaustive search algorithm; 2) Biomarker selection (*middle panel*): A panel of 12 plasma miRNA biomarkers candidates are selected based on the DE of plasma miRNAs in trauma patients and guided by the pro-inflammatory miRNA motif; 3) Biomarker evaluation (*right panel*): The plasma miRNA biomarker candidates are quantified in the cohorts of control subjects (n=24) and trauma patients (n=48), tested for their correlations with various trauma pathophysiological markers, and evaluated for their predictive performance in secondary organ injury after trauma.

Figure 2. Machine learning-guided discovery of pro-inflammatory motifs in miRNAs.
A. The motif identification algorithm and five essential motifs to predict pro-inflammatory miRNA.**B.** Training set – mouse miRNAs (n=33). *First column:* Test results of a dose-dependent CXCL2 response in BMDMs for each miRNA; *Middle 5 columns:* Prediction of pro-inflammatory miRNA by individual motif; *Last column:* prediction of pro-inflammatory miRNA by 5 motifs together. **C.** Test set 1 – mouse miRNAs (n=20). **D**. Test set 2 – human miRNAs (n=38).

Figure 3. Quantification of plasma miRNA biomarkers.
A. Expression of plasma miRNA biomarkers in trauma patients versus healthy controls. Undetectable values were shown as zeros on y-axis. (Healthy: n=24, Trauma: n=48). **B.** Expression of plasma miRNA biomarkers between severe (ISS≤15: n=30) and moderate (ISS>15: n=18) trauma patients. **C.** Heatmap of plasma miRNA biomarker expression. Columns were clustered by Pearson's correlation distance. Rows were grouped by injury severity (health, ISS≤15 and ISS>15) and within groups ranked by sum of Z-scores in descending order. Z score was calculated by subtracting the population mean from an individual miRNA copy number and then dividing the difference by the population standard deviation (n=72). Significance tested by Wilcox test with Holm-Bonferroni correction, ****, $p<0.0001$; ***, $p<0.001$; **, $p<0.01$; *: $p<0.05$. Each horizontal bar in A-B represents a median value.

Figure 4. Plasma miRNAs biomarkers are closely correlated with trauma pathophysiology.
A. Multiplex quantification of plasma mediators and organ injury markers. (Healthy controls: n=24, ISS≤15: n=30, ISS>15: n=18). Significance tested by t test with Benjamini-Hochberg correction (for normally distributed P-selectin, vWF-A2 and VCAM-1) or Wilcox test with Holm-Bonferroni correction (for the other mediators). ****, $p<0.0001$; ***, $p<0.001$; **, $p<0.01$; *, $p<0.05$. Each horizontal bar represents a median value. **B.** Correlation of miRNA biomarker candidates with protein mediator and organ injury markers within the trauma cohorts (n=48).

Figure 5. Plasma miRNAs biomarkers are correlated with clinical organ injury and coagulopathy in trauma.

A. Clinical serology data at time of trauma center arrival. For ALT (alanine transaminase), Alk phos (alkaline phosphatase), BUN (blood urea nitrogen), Creatinine, Lactate, PLT (platelet count), WBC (white blood cell), Hb (Hemoglobin) and Hct (hematocrit), ISS≤15: n=30, ISS>15: n=18; for AST (aspartate transferase), Bilirubin total, INR (the international normalized ratio) and PT (prothrombin time), ISS≤15: n=29, ISS>15: n=17; for PTT (partial thromboplastin time), ISS≤15, n=27; ISS>15, n=16. Significance tested by *t* test with Benjamini-Hochberg correction (for normally distributed BUN, Creatinine, PLT and WBC) or Wilcox test with Holm-Bonferroni correction (for the other clinical data)., ****, $p<0.0001$; ***, $p<0.001$; **, $p<0.01$; *, $p<0.05$. Each horizontal bar represents a median value. **B.** Correlation of miRNA biomarker candidates with clinical injury markers within trauma cohorts. (For ISS (Injury severity score), ALT, Alk phos, BUN, Creatinine, Lactate, PLT, WBC, Hb and Hct, n=48; for AST, Bilirubin total, INR and PT, n=46; for PTT, n=43).

Figure 6. Organ injury prediction in trauma by 12-miRNA biomarkers.
ROC curves of different predictors with area under ROC (AUROC) [95% CI]. Predictions made by the 12-miRNA panel (red) with an AUROC greater than 0.7, as well as predictions based on age and sex (gray), are shown. Calculation was based on random forest modeling and 100-times of 2-fold cross validation within trauma cohorts.

Table 1. Demographic and clinical information of human study subjects.

	Control (n = 24)	**Trauma** (n = 48)
Age, median (range)	30.5 (23-41)	29.0 (19-53)
Sex, male	10 (42%)	31 (65%)
Race		
White	17 (71%)	31 (65%)
African-American or Black	3 (13%)	13 (27%)
Asian	1 (4%)	1 (2%)
Hispanic/Latino	2 (8%)	0 (0%)
Other	1 (4%)	3 (6%)
Mechanism of injury		
MVC	-	30 (63%)
MCC	-	4 (8%)
Ped MVA	-	7 (15%)
Mechanical force	-	3 (6%)
Fall	-	4 (8%)
Injury severity score (ISS)	**-**	15.23(4-43)
Injury characteristics		
Bone fracture	-	45
Muscle injury	-	10
Lung injury	-	8
Splenic injury	-	5
Liver injury	-	1
Stomach injury	-	1
Bowel injury	-	4
Mesenteric injury	-	2
Renal injury	-	1
Aortic injury	-	4
Laboratory		
INR	-	1.033 (0.9-1.6)
PTT, s	-	26.33 (21-85)
Platelets, $\times 10^3$/µl	-	257.2 (47-458)
Lactate, mmol/L	-	3.165 (0.8-10.3)

Demographics with median age (range) or count (percent). MVC: motor vehicle collision, MCC: motorcycle collision, MVA: motor vehicle accident, INR: International Normalized Ratio, PTT: Partial Thromboplastin Time. See also Figure S1.

Table 2. Performance of motifs in capturing pro-inflammatory miRNAs.

Data set	Training set		Test set 1		Test set 2	
Origin	Mouse		Mouse		Human	
Size	33		20		38	
	Sensitivity	Specificity	Sensitivity	Specificity	Sensitivity	Specificity
≥1 motif(s)	100%	100%	92%	86%	84%	69%
.UUC	61%	100%	31%	100%	32%	92%
U..UU.	61%	100%	38%	86%	44%	92%
.A.....UU.	61%	100%	46%	100%	52%	92%
G.UU.	56%	100%	54%	86%	56%	100%
UU...U	56%	100%	38%	100%	36%	77%

Sensitivity and specificity of individual or combined (at least 1) motifs for identifying pro-inflammatory miRNAs.

Table 3. Motif-guided selection of miRNA biomarker candidates in trauma.

miRNA candidates	Sequence with **motifs**
hsa-miR-199a-3p	ACAGUAGUCUGCACA**UUGGUUA**
hsa-miR-145-3p	G**GAUUC**CUGGA**AAUACUGUUC**U
hsa-miR-224-5p	UCAAGUCACUAG**UGGUUCCGU**UUAG
hsa-miR-148a-3p	UCAGUGCACUA**CAGAACUUUG**U
hsa-miR-125a-5p	UCCCU**GAGACCCUUU**AACCUGUGA
hsa-miR-199a-5p	CCCAGU**GUUC**AGACUACCU**GUUC**
hsa-miR-27b-3p	UUCACAGUGGCUAA**GUUC**UGC
hsa-miR-29a-3p	UAGCACCAUCUG**AAAUCGGUUA**
hsa-let-7c-5p	UGAGG**UAGUAGGUUGUAUG**GUU
hsa-miR-125b-2-3p	UCACAAGU**CAGGCUCUUG**GGAC
hsa-miR-95-3p	UUCAACGGG**UAUUUAUUG**AGCA
hsa-miR-145-5p	GUCCA**GUUUUC**CCAGGAAUCCCU

Nucleotides within one or more motifs are bolded and underlined.